Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7407955 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
May, 2025
(1 year, 6 months from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8119648 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Aug, 2023
(a month ago) | |
US8178541 | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Aug, 2023
(a month ago) | |
US7407955 (Pediatric) | BOEHRINGER INGELHEIM | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Nov, 2025
(2 years from now) | |
US8883805 | BOEHRINGER INGELHEIM | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
Nov, 2025
(2 years from now) | |
US8883805 (Pediatric) | BOEHRINGER INGELHEIM | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines |
May, 2026
(2 years from now) | |
US8673927 | BOEHRINGER INGELHEIM | Uses of DPP-IV inhibitors |
May, 2027
(3 years from now) | |
US8673927 (Pediatric) | BOEHRINGER INGELHEIM | Uses of DPP-IV inhibitors |
Nov, 2027
(4 years from now) | |
US10022379 | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Apr, 2029
(5 years from now) | |
US9415016 | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Apr, 2029
(5 years from now) | |
US10973827 | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Apr, 2029
(5 years from now) | |
US10973827 (Pediatric) | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Oct, 2029
(6 years from now) | |
US9415016 (Pediatric) | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Oct, 2029
(6 years from now) | |
US10022379 (Pediatric) | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Oct, 2029
(6 years from now) | |
US9155705 | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
May, 2030
(6 years from now) | |
US8846695 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
Jun, 2030
(6 years from now) | |
US9155705 (Pediatric) | BOEHRINGER INGELHEIM | DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation |
Nov, 2030
(7 years from now) | |
US8846695 (Pediatric) | BOEHRINGER INGELHEIM | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
Dec, 2030
(7 years from now) |
Jentadueto is owned by Boehringer Ingelheim.
Jentadueto contains Linagliptin; Metformin Hydrochloride.
Jentadueto has a total of 18 drug patents out of which 2 drug patents have expired.
Expired drug patents of Jentadueto are:
Jentadueto was authorised for market use on 30 January, 2012.
Jentadueto is available in tablet;oral dosage forms.
Jentadueto can be used as use of a pharmaceutical composition comprising linagliptin, metformin and a basic amino acid to treat type 2 diabetes mellitus, method of treating type 2 diabetes mellitus by administering linagliptin in combination with metformin, method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor, method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin and/or a sulfonylurea.
The generics of Jentadueto are possible to be released after 04 December, 2030.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M (M) | Jun 20, 2026 |
Pediatric Exclusivity (PED) | Dec 20, 2026 |
Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 30 January, 2012
Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor; Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in co...
Dosage: TABLET;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic